NCT06749587View on ClinicalTrials.gov

TEOSYAL RHA® 1 for the Correction of Moderate to Severe Tissue Volume Deficiency in the Infraorbital Region in Chinese Adults

NARecruitingINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

March 12, 2025

Study Completion Date

January 12, 2026

Conditions

Infraorbital Hollows

Interventions

DEVICE

TEOSYAL RHA® 1

"Product injection in infraorbital hollows~TEOSYAL RHA® 1 is a sterile, transparent, non-pyrogenic, viscoelastic gel made of Hyaluronic Acid (HA) of non-animal origin"

Trial Locations (1)

Unknown

RECRUITING

Guangdong Second Provincial General Hospital, Guangzhou

All Listed Sponsors

lead

Teoxane SA

INDUSTRY